Is Bruton tyrosine kinase a potential target to treat mast cell neoplasms? Systemic mastocytosis associated with chronic lymphoid leukemia successfully treated with acalabrutinib monotherapy: a case report and review of the literature.

Fazio M; Elena C; Ferrari J; Camilotto V; Stella S; Leotta D; Palumbo GA; Di Raimondo F; Romano A

doi:10.3324/haematol.2025.289116

← 뒤로

Is Bruton tyrosine kinase a potential target to treat mast cell neoplasms? Systemic mastocytosis associated with chronic lymphoid leukemia successfully treated with acalabrutinib monotherapy: a case report and review of the literature.

증례보고 1/5 보강

Haematologica 📖 저널 OA 87.2% 2021~2026 2025

Fazio M, Elena C, Ferrari J, Camilotto V, Stella S, Leotta D

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓

📝 환자 설명용 한 줄

Not available.

이 논문을 인용하기

↓ .bib ↓ .ris

APA Fazio M, Elena C, et al. (2025). Is Bruton tyrosine kinase a potential target to treat mast cell neoplasms? Systemic mastocytosis associated with chronic lymphoid leukemia successfully treated with acalabrutinib monotherapy: a case report and review of the literature.. Haematologica. https://doi.org/10.3324/haematol.2025.289116

MLA Fazio M, et al.. "Is Bruton tyrosine kinase a potential target to treat mast cell neoplasms? Systemic mastocytosis associated with chronic lymphoid leukemia successfully treated with acalabrutinib monotherapy: a case report and review of the literature.." Haematologica, 2025.

PMID 41376555 ↗

DOI 10.3324/haematol.2025.289116

Abstract

Not available.

같은 제1저자의 인용 많은 논문 (1)

Skeletal Involvement in Systemic Mastocytosis: Pathophysiology, Clinical Management, Standards of Care, and Novel Therapeutic Strategies.
Cells 2026

이 논문을 인용하기

Abstract 한글 요약

같은 제1저자의 인용 많은 논문 (1)

Abstract